Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye
Open accessAbstract
Dry eye syndrome is a prevalent disease that affects visual acuity, activities of daily living, and quality of life. A number of contributory factors affect the severity of dry eye syndrome, including autoimmune disease, environmental surroundings, contact lens use, hormonal changes, anatomical features, chronic inflammation, infections, and iatrogenic factors, such as medications or surgery. Symptoms may include intermittent or constant blurry vision, discomfort, burning, foreign body sensation, hyperemia, dryness, and photophobia. The severity of dry eye syndrome can range from very mild disease to extremely severe cases with vision-threatening consequences. A variety of dry eye treatment modalities exist to address the different causes, symptoms, and consequences of ocular surface disease, including artificial tears, lubricating gels, ophthalmic inserts, anti-inflammatory drops, and surgical procedures. In this paper, an assortment of literature pertaining to the treatment of dry eye syndrome, in particular hydroxypropyl cellulose ophthalmic inserts, is reviewed. These inserts can be used effectively as monotherapy, or in conjunction with other therapies, and should be considered in the treatment of dry eye syndrome.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A combination of chitosan and alginate in nanoparticle formulations, such as alginate-chitosan microspheres, has been shown to extend the retention time of drugs like azelastine in the conjunctival sac and on the corneal surface.
“A combination of chitosan and alginate in nanoparticle formulations, such as alginate-chitosan microspheres, has been shown to extend the retention time of drugs like azelastine in the conjunctival sac and on the corneal surface [62].”
From From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics (2025) · cites this paper as [62]
The Introduction discusses hydroxypropyl cellulose inserts for dry eye, and the Conclusion addresses their safety and effectiveness; neither addresses the claimed formulation. Searches for alginate-chitosan microspheres, azelastine, nanoparticles, and drug retention in the conjunctival sac or on the cornea found no relevant passage in our copy. (LLM, conf=0.77)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 22
- [1]The definition and classification of dry eye disease: Report of the definition and classification subcommittee of the international dry eye workshop (2007) Ocul Surf 2007 5 75 92 17508116
- [2]Latkany R Dry eyes: Etiology and management Curr Opin Ophthalmol 2008 19 287 291 18545008
- [3]Latkany R Lock B Speaker M Tear film normalization test: A new diagnostic test for dry eyes Cornea 2006 25 1153 1157 17172889
- [4]Yuan Y Wang J Chen Q Tao A Shen M Shousha M Reduced tear meniscus dynamics in dry eye patients with aqueous tear deficiency Am J Ophthalmol 2010 149 932 938 20378096 PMC2878896
- [5]Nichols K Nichols J Mitchell G The lack of association between signs and symptoms in patients with dry eye disease Cornea 2004 23 762 770 15502475
- [6]Schein OD Munoz B Tielsch JM Prevalence of dry eye among the elderly Am J Ophthalmol 1997 124 723 728 9402817
- [7]Calonge M The treatment of dry eye Surv Ophthalmol 2001 45 S227 S239 11587147
- [8]Murube J Murube E Treatment of dry eye by blocking the lacrimal canaliculi Surv Ophthalmol 1996 40 463 480 8724639
- [9]Balaram M Schaumberg D Dana MR Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome Am J Ophthalmol 2001 131 30 36 11162976
- [10]Yen M Pflugfelder S Feuer W The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects Am J Ophthalmol 2001 131 314 323 11239863
- [12]Luchs J Nelinson D Macy J Efficacy of hydroxypropyl cellulose ophthalmic inserts (LACRISERT) in subsets of patients with dry eye syndrome: Findings from a patient registry Cornea 2010 29 1417 1427 20847657
- [13]Koffler B McDonald M Nelinson D Improved signs, symptoms, and quality of life associated with dry eye syndrome: Hydroxypropyl cellulose ophthalmic insert patient registry Eye Contact Lens 2010 36 170 176 20351555
- [14]McDonald M D’Aversa G Perry H Wittpenn J Donnenfeld E Nelinson D Hydroxypropyl cellulose ophthalmic inserts (Lacrisert) reduce the signs and symptoms of dry eye syndrome and improve patient quality of life Trans Am Ophthalmol Soc 2009 107 214 221 20126497 PMC2814588
- [15]Wander A Koffler B Extending the duration of tear film protection in dry eye syndrome: Review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert Ocul Surf 2009 7 154 162 19635248
- [16]Mcdonald M D’Aversa G Perry H Wittpenn J Nelinson D Correlating patient-reported response to hydroxypropyl cellulose ophthalmic insert (LACRISERT) therapy with clinical outcomes: Tools for predicting response Curr Eye Res 2010 35 880 887 20858108
- [17]Hill J Slow-release artificial tear inserts in the treatment of dry eyes in patients with rheumatoid arthritis Br J Ophthalmol 1989 73 151 154 2649149 PMC1041674
- [18]Katz J Kaufman H Breslin C Katz I Slow release artificial tears and the treatment of keratitis sicca Ophthalmology 1981 88 78 81 714379
- [19]Tutt R Bradley A Begley C Thibos L Optical and visual impact of tear break-up in human eyes Invest Ophthalmol Vis Sci 2000 41 4117 4123 11095604
- [20]Liu H Thibos L Begley C Bradley A Measurement of the time course of optical quality and visual deterioration during tear break-up Invest Ophthalmol Vis Sci 2010 51 3318 3326 20107168 PMC3990466
- [21]Montés-Micó R Alió J Muñoz G Charman W Temporal changes in optical quality of air-tear film interface at anterior cornea blink Invest Ophthalmol Vis Sci 2004 45 1752 1757 15161836
- [22]Liu Z Pflufelder S Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency Ophthalmology 1999 106 939 943 10328393
- [23]Nilforoushan M Latkany R Speaker M Effect of artificial tears on visual acuity Am J Ophthalmol 2005 140 830 835 16310460
Cited by
Sorted by citations
From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics
Sun, M., Wang, J., Fan, W., Wang, K., Wang, Y., Zhang, J., Ding, S., Zhang, C., Feng, Z., Wang, Y.-G., et al. (2025) · Materials today. Bio · doi:10.1016/j.mtbio.2025.102537 · Cited by 7 · see citing works
A nanomicelles platform delivery system for water-insoluble corticosteroid to treat anterior uveitis
Sathe, P., Kameshwari, S. M. S., & Nirmal, J. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01103-z · Cited by 1 · see citing works
- Authors
- Latkany, R., & Nguyen
- Corresponding author
- Latkany, Robert
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2011-05
- Volume
- 5
- Pages
- 587
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC3102590
- OpenAlex
- W1970847725
- Cited by
- 39
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 6 · 2020: 3 · 2019: 5 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 1 · 2012: 2
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ocular Surface and Contact Lens
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Physiology › Salivary Gland Disorders and Functions
- Keywords
- dry eye, hydroxypropyl cellulose, ophthalmic inserts, ocular surface disease, artificial tears, dry eye treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
